New drug XFB19 enters first human safety trial

NCT ID NCT05361733

Recruiting now Knowledge-focused Sponsor: Xfibra, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is the first time the drug XFB19 is being tested in humans. It aims to check if XFB19 is safe and how the body processes it. Forty healthy adults aged 18 to 55 will receive either XFB19 or a placebo. The trial is run by Xfibra, Inc. and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

XFB19

What this could lead to

If safe, this could pave the way for future studies of XFB19 in inflammatory or fibrotic diseases.

What could go wrong

This is a very early Phase 1 trial in only 40 healthy people. It only tests safety, not whether the drug works for any disease. Many drugs fail at this stage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOCUS OF THE STUDY: SAFETY OF XFB19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOCUS OF THE STUDY: SAFETY OF XFB19

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AMR Clinical
RECRUITING

Knoxville, Tennessee, 37920, United States